RU97113495A - APPLICATION OF 3,4-DIPHENYL CHROMANS FOR OBTAINING A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF IDIOPATHIC OR PHYIOLOGICAL GYNECOMMOSTIA - Google Patents
APPLICATION OF 3,4-DIPHENYL CHROMANS FOR OBTAINING A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF IDIOPATHIC OR PHYIOLOGICAL GYNECOMMOSTIAInfo
- Publication number
- RU97113495A RU97113495A RU97113495/14A RU97113495A RU97113495A RU 97113495 A RU97113495 A RU 97113495A RU 97113495/14 A RU97113495/14 A RU 97113495/14A RU 97113495 A RU97113495 A RU 97113495A RU 97113495 A RU97113495 A RU 97113495A
- Authority
- RU
- Russia
- Prior art keywords
- use according
- compound
- idiopathic
- gynecomastia
- enantiomer
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims 2
- 230000002265 prevention Effects 0.000 title claims 2
- 239000004305 biphenyl Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 11
- 201000000079 gynecomastia Diseases 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- 125000001302 tertiary amino group Chemical group 0.000 claims 2
- XZEUAXYWNKYKPL-URLMMPGGSA-N Ormeloxifene Chemical compound C1([C@@H]2[C@H](C3=CC=C(C=C3OC2(C)C)OC)C=2C=CC(OCCN3CCCC3)=CC=2)=CC=CC=C1 XZEUAXYWNKYKPL-URLMMPGGSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002500 effect on skin Effects 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 239000007943 implant Substances 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 229960003327 ormeloxifene Drugs 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
Claims (1)
в которой R1, R4 и R5 индивидуально представляют водород, гидрокси, галоген, трифторметил, низший алкил, низший алкокси или (третичный амино) (низший алкокси), R2 и R3 представляют индивидуально водород или низший алкил, или в виде их фармацевтически приемлемой соли в комбинации с фармацевтически приемлемым носителем для получения фармацевтической композиции для лечения или профилактики идиопатической или физиологической гинекомастии.1. The use of compounds of General formula I
in which R1, R4 and R5 individually represent hydrogen, hydroxy, halogen, trifluoromethyl, lower alkyl, lower alkoxy or (tertiary amino) (lower alkoxy), R2 and R3 represent individually hydrogen or lower alkyl, or as their pharmaceutically acceptable salt in combination with a pharmaceutically acceptable carrier for the preparation of a pharmaceutical composition for the treatment or prevention of idiopathic or physiological gynecomastia.
8. Применение по п.1, в котором указанное соединение представляет выделенный d- или l-энантиомер.7. The use according to claim 1, in which R5 represents a group as indicated in formula II
8. The use according to claim 1, wherein said compound is an isolated d- or l-enantiomer.
10. Применение по одному из предыдущих пунктов, в котором указанное соединение представляет выделенный l-энантиомер.9. The use according to claim 1, in which the specified connection has the General formula III
10. The use according to one of the preceding claims, in which said compound is the isolated l-enantiomer.
12. Применение по п. 11, в котором указанное соединение представляет выделенный d- или l-энантиомер.11. The use according to claim 1, wherein said compound is centchroman having formula IV as follows:
12. The use according to claim 11, wherein said compound is an isolated d- or l-enantiomer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK0042/95 | 1995-01-13 | ||
DK0773/95 | 1995-06-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
RU97113495A true RU97113495A (en) | 1999-07-20 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR960700708A (en) | METHDOS FOR INHIBITING BONE LOSS WITH 3,4-DIARYLCHROMAN | |
RU95122775A (en) | METHOD FOR REDUCING BONE TISSUE LOSS, METHOD FOR TREATING OSTEOPOROSIS AND CONNECTION | |
ES2295609T3 (en) | TIADIAZOLILPIPERAZINA DERIVATIVES USEFUL TO TREAT OR PREVENT A PAIN. | |
RU93051780A (en) | CONTROLLED RELEASE COMPOSITIONS CONTAINING OXYCODONE, METHOD FOR REDUCING DAILY DOSES OF PRODUCTS CONTAINING OXYCODON | |
MXPA04012998A (en) | Tricyclic steroid hormone nuclear receptor modulators. | |
DE69613365T2 (en) | ESTER OF 5-AMINOLEVULINIC ACID AS A MEDICINE FOR PHOTOSENSITIZATION IN CHEMOTHERAPY | |
EP1862458A3 (en) | Therapeutic agents useful for treating pain | |
RU2008103617A (en) | BISPHOSPHONIC ACIDS INTENDED FOR TREATMENT AND PREVENTION OF OSTEOPOROSIS | |
EP0911331A3 (en) | Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use | |
CA2015475A1 (en) | Treating agent for osteoarthritis | |
BRPI0405657A (en) | Method for the treatment of and treatment for severe heart failure | |
EP0779889A4 (en) | PYRAZOLO 3,4-g]QUINOXALINE COMPOUNDS WHICH INHIBIT PDGF RECEPTOR PROTEIN TYROSINE KINASE | |
RU96115938A (en) | USE OF DERIVATIVES 2,3-DIARYL-1-BENZOPIRANE FOR THE PRODUCTION OF MEDICINE IN THE TREATMENT AND PREVENTION OF BONE LOSSES AND OSTEOPOROSIS | |
ZA922910B (en) | Heterocylic pharmaceutical compounds preparation and use | |
RU98103388A (en) | (R) -5-BROM-N- (1-ETHYL-4-Methylhexagidro-1H-1,4-Diazepin-6-IL) -2-METHOXI-6-M COMPOSITION CONTAINING THE SPECIFIED CONNECTION | |
RU2004131214A (en) | METHODS FOR TREATING COGNITIVE DISORDERS | |
RU96103685A (en) | 1,2,5-TIADIAZOLIC DERIVATIVES OF INDOLALALKYL-PYRIDINIL-PYRIMIDINIL-PIPERAZINES, METHOD OF TREATMENT OR PREVENTION OF THE DEVELOPMENT OF VASCULAR HEADACHE AND PHARMACEUTICAL COMPOSITION | |
EP0743065A3 (en) | Vanadium compounds for inhibiting bone loss | |
RU2004121687A (en) | COMPOSITIONS CONTAINING EPOTHYLONS AND THEIR APPLICATION FOR TREATMENT OF A CARCINOID SYNDROME | |
RU97113495A (en) | APPLICATION OF 3,4-DIPHENYL CHROMANS FOR OBTAINING A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF IDIOPATHIC OR PHYIOLOGICAL GYNECOMMOSTIA | |
BG106180A (en) | Pharmaceutical composition containing sibutramine and orlistat | |
RU99118510A (en) | COMPOSITION FOR THE TREATMENT OR PREVENTION OF PROSTATE CANCER | |
WO2001068076A8 (en) | D-enantiomer of dfmo and methods of use thereof for treating cancer | |
RU98101105A (en) | NEW APPLICATION FOR MEDICAL PURPOSES | |
RU2000102642A (en) | MEDICAL MEANS AGAINST AloPETIA |